Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$68.80

1.07 (1.58%)

16:10
10/23/19
10/23
16:10
10/23/19
16:10

BioMarin reports Q3 EPS 30c, consensus 6c

Reports Q3 revenue $461.1M, consensus $454.55M. Vimizim Net Product Revenues increased by $40.2M, or 33%; Palynziq Net Product Revenues increased by $20.0M; Brineura Net Product Revenues increased by $9.9M; or 100%; Kuvan Net Product Revenues increased by $7.3M, or 6%; Naglazyme Net Product Revenues decreased by $8.7M, or 8%; Aldurazyme Net Product Revenues decreased $4.8M. CEO Jean-Jacques Bienaime said, "BioMarin is entering a stage that I believe will bring significant growth as we get closer to submitting marketing applications for valoctocogene roxaparvovec for severe hemophilia A and a pivotal data read-out for vosoritide for children with achondroplasia. These potential new products, combined with our strong base business and continued financial discipline, position us for significant growth and expansion beginning in the very near future. Later this quarter, both the U.S. and European marketing applications for valoctocogene roxaparvovec for severe hemophilia A will be submitted. If the applications are approved, we could potentially be launching the first approved gene therapy product in hemophilia A in the second half of 2020. We are also encouraged by the recent recommendation by the EMA to grant our request for accelerated assessment of valoctocogene roxaparvovec for severe hemophilia A. We are very pleased with the level of engagement we have had with global health authorities, as it aligns with our belief that gene therapy will be the next wave of innovation for treating people with severe hemophilia A."

  • 23

    Oct

  • 07

    Dec

BMRN BioMarin
$68.80

1.07 (1.58%)

09/13/19
PIPR
09/13/19
NO CHANGE
Target $120
PIPR
Overweight
Piper a buyer of BioMarin shares into next important data catalyst
Piper Jaffray analyst Christopher Raymond sees the vosoritide Phase 3 achondroplasia data, expected by early 2020, as the next important catalyst for shares of BioMarin Pharmaceutical. Assuming no surprises, vosoritide offers a "compelling" commercial premise, with "meaningful" upside to current expectations with little in the way of meaningful competition on the horizon, Raymond tells investors in a research note. The analyst is a buyer into the data and keeps an Overweight rating on BioMarin shares with a $120 price target.
10/09/19
STFL
10/09/19
NO CHANGE
STFL
Hold
Bluebird Hem A collaboration not stock moving, but worth monitoring, says Stifel
Stifel analyst Benjamin Burnett said he does not expect news that Blubird Bio (BLUE) is entering the Hemophila A race via a collaboration with Novo Nordisk (NVO) to be stock moving, but he does think it is "certainly worth monitoring." Biomarin's (BMRN) gene therapy candidate Valrox sets "the bar for genetic medicines in heme A today," said Burnett, who noted that gene therapies from Spark (ONCE) and Pfizer (PFE) are also in the clinic. However, "there does appear to be room for efficacy improvement as none of the clinical data generated from genetic medicines to date is a clear home run," Burnett added in his note to investors. He keeps a Hold rating on Bluebird Bio shares.
10/16/19
BOFA
10/16/19
INITIATION
Target $90
BOFA
Buy
BioMarin reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of BioMarin with a Buy rating and $90 price target, highlighting the base business's above average growth and a new product cycle on the way.
10/21/19
CANT
10/21/19
NO CHANGE
Target $129
CANT
Overweight
Cantor sees successful vosoritide Phase 3 trial for BioMarin by year end
Cantor Fitzgerald analyst Eliana Merle reiterates an Overweight rating on BioMarin with a $129 price target saying she has "high conviction" in a successful vosoritide Phase 3 trial by the end of 2019. This will be a key catalyst of focus for the shares, Merle tells investors in a research note. The analyst hosted Dr. Jonathan Day, the clinical lead for BioMarin's vosoritide program for achondroplasia, for a conference call on Friday and thinks Day sounded highly confident in Phase 3 success for vosoritide, "especially given powering assumptions." Merle thinks a successful Phase 3 will support further near-term revenue growth and profitability for BioMarin. On a successful Phase 3, the shares could trade up 10%-20% versus downside risk of ~20%, contends the analyst.

TODAY'S FREE FLY STORIES

PAYC

Paycom

$239.80

4.63 (1.97%)

06:39
11/20/19
11/20
06:39
11/20/19
06:39
Upgrade
Paycom rating change  »

Paycom upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

QCOM

Qualcomm

$87.95

-2.52 (-2.79%)

06:39
11/20/19
11/20
06:39
11/20/19
06:39
Recommendations
Qualcomm analyst commentary  »

Qualcomm positioned well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.86

0.27 (0.24%)

06:38
11/20/19
11/20
06:38
11/20/19
06:38
Hot Stocks
Breaking Hot Stocks news story on Target »

Target up 8.3% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

AVY

Avery Dennison

$131.42

0.26 (0.20%)

06:38
11/20/19
11/20
06:38
11/20/19
06:38
Hot Stocks
Avery Dennison to acquire Smartrac's RFID Inlay business for EUR225M »

Avery Dennison announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$110.86

0.27 (0.24%)

06:37
11/20/19
11/20
06:37
11/20/19
06:37
Earnings
Breaking Earnings news story on Target »

Target raises FY19 adj…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

ADSK

Autodesk

$164.53

2.08 (1.28%)

06:37
11/20/19
11/20
06:37
11/20/19
06:37
Recommendations
Autodesk analyst commentary  »

Autodesk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

QIWI

Qiwi

$20.14

0.38 (1.92%)

06:36
11/20/19
11/20
06:36
11/20/19
06:36
Earnings
Qiwi raises FY19 adjusted revenue growth view to 15%-19% from 9%-15% »

Consensus for FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

TGT

Target

$110.86

0.27 (0.24%)

06:35
11/20/19
11/20
06:35
11/20/19
06:35
Earnings
Target sees Q4 adj. EPS $1.54-$1.75, consensus $1.65 

Sees Q4 SSS up 3%-4%.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TJX

TJX

$60.66

1.12 (1.88%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Recommendations
TJX analyst commentary  »

Nomura Instinet lists…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

T

AT&T

$38.00

-1.61 (-4.06%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Recommendations
AT&T analyst commentary  »

KeyBanc data shows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

  • 29

    Jan

LLY

Eli Lilly

$115.13

1.04 (0.91%)

06:34
11/20/19
11/20
06:34
11/20/19
06:34
Hot Stocks
Eli Lilly to invest $400M in Indianapolis manufacturing facilities »

Eli Lilly announced plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 30

    Jan

TGT

Target

$110.86

0.27 (0.24%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Earnings
Target reports Q3 adj. EPS $1.36, consensus $1.19 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CDXC

ChromaDex

$3.49

0.19 (5.76%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Hot Stocks
ChromaDex: EC votes in favor on Nicotinamide Riboside Chloride as a novel food »

ChromaDex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QIWI

Qiwi

$20.14

0.38 (1.92%)

06:33
11/20/19
11/20
06:33
11/20/19
06:33
Earnings
Qiwi reports Q3 EPS 29c, one estimate 33c »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

EVRG

Evergy

$64.79

-0.19 (-0.29%)

06:29
11/20/19
11/20
06:29
11/20/19
06:29
Downgrade
Evergy rating change  »

Evergy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RES

RPC, Inc.

$3.84

-0.015 (-0.39%)

06:26
11/20/19
11/20
06:26
11/20/19
06:26
Downgrade
RPC, Inc. rating change  »

RPC, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$5.63

-0.295 (-4.98%)

06:24
11/20/19
11/20
06:24
11/20/19
06:24
Downgrade
Qudian rating change  »

Qudian downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

06:22
11/20/19
11/20
06:22
11/20/19
06:22
Periodicals
WeWork began layoffs on Monday, Business Insider reports »

WeWork's layoffs…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

06:21
11/20/19
11/20
06:21
11/20/19
06:21
Downgrade
Berry Petroleum rating change  »

Wells Fargo downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBCP

Concrete Pumping

$3.88

0.17 (4.58%)

06:21
11/20/19
11/20
06:21
11/20/19
06:21
Conference/Events
Concrete Pumping management to meet with William Blair »

Luncheon Meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

EVRG

Evergy

$64.79

-0.19 (-0.29%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Downgrade
Evergy rating change  »

Evergy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.03

-1.85 (-10.96%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Periodicals
Macy's confirms 'targeted data security incident' impacted customers, WSJ says »

Macy's says customer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

AL

Air Lease

$45.16

0.435 (0.97%)

06:20
11/20/19
11/20
06:20
11/20/19
06:20
Conference/Events
Air Lease management to meet with Stephens »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

06:19
11/20/19
11/20
06:19
11/20/19
06:19
Downgrade
Berry Petroleum rating change  »

KeyBanc downgrades Berry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XGN

Exagen

$19.25

-0.04 (-0.21%)

06:19
11/20/19
11/20
06:19
11/20/19
06:19
Conference/Events
Exagen management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.